Aptamers are emerging as powerful “chemical antibodies” that can bind targets with high precision while offering advantages in design, synthesis, and stability. In this episode, we explore how these short nucleic acid ligands are selected, how they work, and why they are gaining attention as next-generation tools for diagnostics, targeted delivery, and therapy. We also discuss their potential to reshape future medicine, along with the key challenges that must be solved for broader clinical use.
Podden och tillhörande omslagsbild på den här sidan tillhör
Vinod Reddy Lekkala. Innehållet i podden är skapat av Vinod Reddy Lekkala och inte av,
eller tillsammans med, Poddtoppen.
